Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ocular surface changes after switching to tafluprost and preservative-free tafluprost in glaucoma
TCTR20170420001Phase 4Recruiting
- Sponsor
- Santen Pharmaceutical
- Start
- Jan 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of tafluprost in Glaucoma, sponsored by Santen Pharmaceutical. Started Jan 2017; status: recruiting.
02
Drugs
tafluprost
03
Conditions
Glaucoma
Beyond the preview
Go deeper on TCTR20170420001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20170420001.